Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy

BACKGROUND: Dalfampridine improves walking speed in patients with multiple sclerosis (MS), but accessing specialty medications such as dalfampridine can be hindered by insurance restrictions, high costs, and limited distribution networks (LDNs) imposed by manufacturers. Some integrated health-system...

Full description

Bibliographic Details
Main Authors: Banks, A. (Author), Choi, L. (Author), DeClercq, J. (Author), Givens, G. (Author), Markley, B. (Author), Peter, M.E (Author), Zuckerman, A.D (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
4-Aminopyridine
adult
Article
Caucasian
clinical outcome
clinical pharmacist
controlled study
decision making
drug therapy
electronic health record
Expanded Disability Status Scale
fampridine
female
Female
health care access
health care delivery
health care management
health care planning
health care system
health insurance
Health Services Accessibility
Health Systems Plans
hospital admission
human
Humans
limited distribution drug network
logistic regression analysis
major clinical study
male
Male
Medical Assistance
medical care
middle aged
Middle Aged
multiple sclerosis
Multiple Sclerosis
myelitis
nursing staff
organization and management
patient care
Pharmaceutical Services
pharmacy (shop)
pharmacy technician
prescription
prior authorization
Retrospective Studies
retrospective study
specialty pharmacy
treatment indication
United States
walk test
walking
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items